{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:17:13Z","timestamp":1783772233847,"version":"3.55.0"},"reference-count":145,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830093"],"award-info":[{"award-number":["81830093"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Marine Drugs"],"abstract":"<jats:p>Worldwide, 19.3 million new cancer cases and almost 10.0 million cancer deaths occur each year. Recently, much attention has been paid to the ocean, the largest biosphere of the earth that harbors a great many different organisms and natural products, to identify novel drugs and drug candidates to fight against malignant neoplasms. The marine compounds show potent anticancer activity in vitro and in vivo, and relatively few drugs have been approved by the U.S. Food and Drug Administration for the treatment of metastatic malignant lymphoma, breast cancer, or Hodgkin\u2032s disease. This review provides a summary of the anticancer effects and mechanisms of action of selected marine compounds, including cytarabine, eribulin, marizomib, plitidepsin, trabectedin, zalypsis, adcetris, and OKI-179. The future development of anticancer marine drugs requires innovative biochemical biology approaches and introduction of novel therapeutic targets, as well as efficient isolation and synthesis of marine-derived natural compounds and derivatives.<\/jats:p>","DOI":"10.3390\/md19090488","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T22:49:51Z","timestamp":1630363791000},"page":"488","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms"],"prefix":"10.3390","volume":"19","author":[{"given":"Lichuan","family":"Wu","sequence":"first","affiliation":[{"name":"Medical College, Guangxi University, Nanning 530004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ye","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-2316","authenticated-orcid":false,"given":"Guangbiao","family":"Zhou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1039\/C7NP00052A","article-title":"Marine natural products","volume":"35","author":"Blunt","year":"2018","journal-title":"Nat. Prod. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1039\/C8NP00092A","article-title":"Marine natural products","volume":"36","author":"Carroll","year":"2019","journal-title":"Nat. Prod. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1021\/acsmedchemlett.8b00368","article-title":"Marine Natural Products in Medicinal Chemistry","volume":"9","author":"Jimenez","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Khalifa, S.A.M., Elias, N., Farag, M.A., Chen, L., Saeed, A., Hegazy, M.F., Moustafa, M.S., Abd El-Wahed, A., Al-Mousawi, S.M., and Musharraf, S.G. (2019). Marine Natural Products: A Source of Novel Anticancer Drugs. Mar. Drugs, 17.","DOI":"10.3390\/md17090491"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/13543776.2019.1598972","article-title":"Marine natural products as source of new drugs: A patent review (2015\u20132018)","volume":"29","author":"Shinde","year":"2019","journal-title":"Expert. Opin. Pat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"112631","DOI":"10.1016\/j.ejmech.2020.112631","article-title":"Current development of CFTR potentiators in the last decade","volume":"204","author":"Spano","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Barreca, M., Span\u00f2, V., Montalbano, A., Cueto, M., and Bertoni, F. (2020). Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. Mar. Drugs, 18.","DOI":"10.3390\/md18120619"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12023","DOI":"10.1021\/acs.jmedchem.0c01315","article-title":"Pyrrolo[2\u2032,3\u2032:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types","volume":"63","author":"Rocca","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1021\/acs.jmedchem.6b00777","article-title":"Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma","volume":"59","author":"Pennati","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1158\/1078-0432.CCR-11-1107","article-title":"Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I","volume":"17","author":"Sippel","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(00)00292-8","article-title":"Marine organisms as a source of new anticancer agents","volume":"2","author":"Schwartsmann","year":"2001","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1073\/pnas.97.4.1885","article-title":"Induction of topoisomerase I cleavage complexes by 1-beta-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells","volume":"97","author":"Pourquier","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","first-page":"157","article-title":"Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L-1210 cells","volume":"25","author":"Nakayama","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V62.2.361.361","article-title":"High-dose cytosine arabinoside therapy for refractory leukemia","volume":"62","author":"Herzig","year":"1983","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00321053","article-title":"High-dose cytosine arabinoside: Pharmacological and clinical aspects","volume":"56","author":"Peters","year":"1988","journal-title":"Blut"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1200\/JCO.1990.8.9.1531","article-title":"Prevention of cyclophosphamide\/cytarabine-induced emesis with ondansetron in children with leukemia","volume":"8","author":"Carden","year":"1990","journal-title":"J. Clin."},{"key":"ref_19","first-page":"3411","article-title":"Observation of clinical efficacy and toxic and side effects of pirarubicin combined with cytarabine on acute myeloid leukemia","volume":"17","author":"Lv","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/cts.12366","article-title":"ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression","volume":"9","author":"Drenberg","year":"2016","journal-title":"Clin. Transl. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1186\/2193-1801-3-732","article-title":"Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine","volume":"3","author":"Adema","year":"2014","journal-title":"Springerplus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-2952(98)00224-X","article-title":"Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target","volume":"57","author":"Waddick","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/7410","article-title":"Control of inducible chemoresistance: Enhanced antitumor therapy through increased apoptosis by inhibition of NF-kappaB","volume":"5","author":"Wang","year":"1999","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0093-7754(01)90036-3","article-title":"The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma","volume":"28","author":"Berenson","year":"2001","journal-title":"Semin. Oncol."},{"key":"ref_25","first-page":"3535","article-title":"Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition","volume":"61","author":"Cusack","year":"2001","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1038\/srep06048","article-title":"Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia","volume":"4","author":"Rathe","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1351\/pac198658050701","article-title":"Halichondrins\u2014Antitumor polyether macrolides from a marine sponge","volume":"58","author":"Hirata","year":"1986","journal-title":"Pure Appl. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1016\/j.bmcl.2004.08.068","article-title":"Structurally simplified macrolactone analogues of halichondrin B","volume":"14","author":"Seletsky","year":"2004","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/1758834017712963","article-title":"Treatment of advanced, metastatic soft tissue sarcoma: Latest evidence and clinical considerations","volume":"9","author":"In","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14876","article-title":"Enriching cancer pharmacology with drugs of marine origin","volume":"177","author":"Jimenez","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/OTT.S102638","article-title":"Efficacy of eribulin in breast cancer: A short report on the emerging new data","volume":"10","author":"Eslamian","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_32","first-page":"1611","article-title":"Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): Optimal effectiveness under intermittent dosing conditions","volume":"32","author":"Towle","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"22986","DOI":"10.18632\/oncotarget.25184","article-title":"Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances antitumor effects on triple-negative breast cancer through mesenchymal-epithelial transition","volume":"9","author":"Oba","year":"2018","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/sj.emboj.7601009","article-title":"Progressively impaired proteasomal capacity during terminal plasma cell differentiation","volume":"25","author":"Cenci","year":"2006","journal-title":"EMBO J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.bmc.2008.10.075","article-title":"Discovery and development of the anticancer agent salinosporamide A (NPI-0052)","volume":"17","author":"Fenical","year":"2009","journal-title":"Bioorganic Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.bjc.6603406","article-title":"A novel proteasome inhibitor NPI-0052 as an anticancer therapy","volume":"95","author":"Chauhan","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.4049\/jimmunol.180.9.6199","article-title":"Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells","volume":"180","author":"Baritaki","year":"2008","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/bjc.1998.183","article-title":"The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis","volume":"77","author":"Delic","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2404444","article-title":"Proteasome inhibitors: Antitumor effects and beyond","volume":"21","author":"Nencioni","year":"2007","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.13780","article-title":"Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide","volume":"171","author":"Das","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.seminoncol.2013.07.005","article-title":"Novel generation of agents with proven clinical activity in multiple myeloma","volume":"40","author":"Mateos","year":"2013","journal-title":"Semin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2174\/09298673113209990122","article-title":"Clinical and marketed proteasome inhibitors for cancer treatment","volume":"20","author":"Zhang","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2013.10.018","article-title":"New orally active proteasome inhibitors in multiple myeloma","volume":"38","author":"Allegra","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1517\/14740338.2014.939953","article-title":"An analysis of the safety profile of proteasome inhibitors for treating various cancers","volume":"13","author":"Wang","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0304-3835(96)04151-1","article-title":"Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates","volume":"102","author":"Urdiales","year":"1996","journal-title":"Cancer Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/jm960048g","article-title":"Structure--activity relationships of the didemnins","volume":"39","author":"Sakai","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1358\/dot.2020.56.5.3135886","article-title":"Plitidepsin to treat multiple myeloma","volume":"56","author":"Gomes","year":"2020","journal-title":"Drugs Today"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.cdd.4401898","article-title":"Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation","volume":"13","author":"Suarez","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s10637-011-9740-3","article-title":"The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells","volume":"30","author":"Morande","year":"2012","journal-title":"Investig. New Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1038\/sj.onc.1205972","article-title":"Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta","volume":"21","author":"Losada","year":"2002","journal-title":"Oncogene"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/sj.bjc.6602166","article-title":"Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin","volume":"91","author":"Losada","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"35100","DOI":"10.1038\/srep35100","article-title":"Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin","volume":"6","author":"Losada","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Borjan, B., Steiner, N., Karbon, S., Kern, J., Francesch, A., Hermann, M., Willenbacher, W., Gunsilius, E., and Untergasser, G. (2015). The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1729-4"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: A retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(15)70070-7","article-title":"Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): A non-randomised, multicentre, phase 2 trial","volume":"16","author":"Pautier","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): A unique mechanism of action","volume":"9","author":"Galmarini","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1021\/jo00302a007","article-title":"Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata","volume":"55","author":"Rinehart","year":"1990","journal-title":"J. Org. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1021\/jo00302a006","article-title":"Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata","volume":"55","author":"Wright","year":"1990","journal-title":"J. Org. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"13028","DOI":"10.1021\/ja983091x","article-title":"Molecular Basis for the DNA Sequence Selectivity of Ecteinascidin 736 and 743:\u2009 Evidence for the Dominant Role of Direct Readout via Hydrogen Bonding","volume":"120","author":"Seaman","year":"1998","journal-title":"J. Am. Chem. Soc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1021\/ja974109r","article-title":"Mechanism for the Catalytic Activation of Ecteinascidin 743 and Its Subsequent Alkylation of Guanine N2","volume":"120","author":"Moore","year":"1998","journal-title":"J. Am. Chem. Soc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.chembiol.2011.06.007","article-title":"XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids","volume":"18","author":"Feuerhahn","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1158\/1078-0432.CCR-08-0730","article-title":"Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin","volume":"14","author":"Aune","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/1535-7163.MCT-08-0848","article-title":"Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors","volume":"8","author":"Forni","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1358\/dot.2020.56.10.3187001","article-title":"Trabectedin for the therapy of ovarian cancer","volume":"56","author":"Evangelisti","year":"2020","journal-title":"Drugs Today"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cam4.3903","article-title":"Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer","volume":"10","author":"Jones","year":"2021","journal-title":"Cancer Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e658","DOI":"10.1002\/onco.13630","article-title":"A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer","volume":"26","author":"Pignata","year":"2021","journal-title":"Oncologist"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Palmerini, E., Sanfilippo, R., Grignani, G., Buonadonna, A., Romanini, A., Badalamenti, G., Ferraresi, V., Vincenzi, B., Comandone, A., and Pizzolorusso, A. (2021). Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. Cancers, 13.","DOI":"10.3390\/cancers13051053"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1002\/cncr.33120","article-title":"Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group","volume":"126","author":"Grosso","year":"2020","journal-title":"Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.19.03289","article-title":"Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups","volume":"38","author":"Gronchi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3390\/md12020719","article-title":"Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment","volume":"12","author":"Carlos","year":"2014","journal-title":"Mar. Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neo.2017.03.004","article-title":"Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models","volume":"19","author":"Tornin","year":"2017","journal-title":"Neoplasia"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Acikgoz, E., Guven, U., Duzagac, F., Uslu, R., Kara, M., Soner, B., and Oktem, G. (2015). Enhanced G2\/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141090"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/1541-7786.MCR-18-0575","article-title":"The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability","volume":"17","author":"Tumini","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/toxins3070848","article-title":"Immunotoxins and anticancer drug conjugate assemblies: The role of the linkage between components","volume":"3","author":"Dosio","year":"2011","journal-title":"Toxins"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14712598.2015.1130821","article-title":"Salvage treatment for relapsed\/refractory Hodgkin lymphoma: Role of allografting, brentuximab vedotin and newer agents","volume":"16","author":"Martino","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PPO.0000000000000168","article-title":"Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma","volume":"22","author":"Alperovich","year":"2016","journal-title":"Cancer J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11864-021-00840-5","article-title":"Novel Therapies in the Treatment of Hodgkin Lymphoma","volume":"22","author":"Ansell","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_82","first-page":"3736","article-title":"The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin\u2019s disease","volume":"62","author":"Wahl","year":"2002","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies","volume":"21","author":"Ducry","year":"2010","journal-title":"Bioconjugate Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CCO.0b013e32834bb8a7","article-title":"CD30-targeted antibody therapy","volume":"23","author":"Younes","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5045\/br.2017.52.4.243","article-title":"Brentuximab vedotin: Clinical updates and practical guidance","volume":"52","author":"Yi","year":"2017","journal-title":"Blood Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"107552","DOI":"10.1016\/j.pharmthera.2020.107552","article-title":"An overview on anti-tubulin agents for the treatment of lymphoma patients","volume":"211","author":"Barreca","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"12328","DOI":"10.3390\/molecules190812328","article-title":"PM00104 (Zalypsis(R)): A marine derived alkylating agent","volume":"19","author":"Petek","year":"2014","journal-title":"Molecules"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bcp.2009.04.003","article-title":"Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines","volume":"78","author":"Leal","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1182\/blood-2008-09-177774","article-title":"Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks","volume":"113","author":"Ocio","year":"2009","journal-title":"Blood"},{"key":"ref_93","first-page":"1384","article-title":"Antitumor activity of the novel investigational compound PM00104","volume":"65","author":"Elices","year":"2005","journal-title":"Cancer Res."},{"key":"ref_94","first-page":"C62","article-title":"Antitumor activity of Zalypsis\u00ae (PM00104) in experimental models of bladder, gastric and liver cancer","volume":"6","author":"Lepage","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_95","first-page":"147","article-title":"The novel compound PM00104 exhibits significant in vivo activity against breast tumors. PM00104 exhibits significant in vivo activity against breast tumors","volume":"65","author":"Elices","year":"2005","journal-title":"Cancer Res."},{"key":"ref_96","first-page":"3545S","article-title":"Preclinical evaluation of PM00104 to support the selection of tumor indications for clinical development","volume":"6","author":"Greiner","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1158\/1535-7163.MCT-09-0336","article-title":"Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition","volume":"8","author":"Antony","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3324\/haematol.2010.036400","article-title":"Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response","volume":"96","author":"Colado","year":"2011","journal-title":"Haematologica"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/onc.2016.344","article-title":"HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer","volume":"36","author":"Stojanovic","year":"2017","journal-title":"Oncogene"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pros.23467","article-title":"Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer","volume":"78","author":"McLeod","year":"2018","journal-title":"Prostate"},{"key":"ref_102","first-page":"116","article-title":"Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells","volume":"55","author":"Maiti","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ejh.13188","article-title":"Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies","volume":"102","author":"Sayehli","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/epi.14.62","article-title":"Isoform-selective histone deacetylase inhibitors: The trend and promise of disease treatment","volume":"7","author":"Zhang","year":"2015","journal-title":"Epigenomics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1039\/b703830p","article-title":"Isoform-selective histone deacetylase inhibitors","volume":"37","author":"Bieliauskas","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1349-7006.2007.00678.x","article-title":"Loss of nephronectin promotes tumor progression in malignant melanoma","volume":"99","author":"Kuphal","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1021\/ja8013727","article-title":"Total synthesis and molecular target of largazole, a histone deacetylase inhibitor","volume":"130","author":"Ying","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1021\/ol801532s","article-title":"Synthesis and activity of largazole analogues with linker and macrocycle modification","volume":"10","author":"Ying","year":"2008","journal-title":"Org. Lett."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"11219","DOI":"10.1021\/ja8033763","article-title":"Total synthesis and biological mode of action of largazole: A potent class I histone deacetylase inhibitor","volume":"130","author":"Bowers","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ejphar.2014.06.019","article-title":"Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization","volume":"740","author":"Zhou","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/liv.12034","article-title":"A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-beta and vascular endothelial growth factor signalling","volume":"33","author":"Liu","year":"2013","journal-title":"Liver Int."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1021\/ml1002794","article-title":"In Vitro and In Vivo Osteogenic Activity of Largazole","volume":"2","author":"Lee","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11101-013-9292-6","article-title":"Natural products as leads to antitumor drugs","volume":"13","author":"Newman","year":"2013","journal-title":"Phytochem. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1021\/ml400093y","article-title":"Largazole Arrests Cell Cycle at G1 Phase and Triggers Proteasomal Degradation of E2F1 in Lung Cancer Cells","volume":"4","author":"Wu","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1124\/jpet.110.172387","article-title":"Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor","volume":"335","author":"Liu","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/onc.2012.138","article-title":"Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms","volume":"32","author":"Law","year":"2013","journal-title":"Oncogene"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/acschembio.5b00860","article-title":"Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer","volume":"11","author":"Bousquet","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/nar\/gkx1225","article-title":"Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers","volume":"46","author":"Sanchez","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1021\/acschemneuro.0c00093","article-title":"Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases","volume":"11","author":"Elsadek","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_121","first-page":"1274","article-title":"Suppression of Musashi-2 by the small compound largazole exerts inhibitory effects on malignant cells","volume":"56","author":"Min","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1016\/j.bmc.2015.03.063","article-title":"Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole","volume":"23","author":"Clausen","year":"2015","journal-title":"Bioorganic Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"10642","DOI":"10.1021\/acs.jmedchem.6b01271","article-title":"Largazole Analogues Embodying Radical Changes in the Depsipeptide Ring: Development of a More Selective and Highly Potent Analogue","volume":"59","author":"Almaliti","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/ml400470s","article-title":"Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors","volume":"5","author":"Chen","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1021\/ja205972n","article-title":"Structural Basis of the Antiproliferative Activity of Largazole, a Depsipeptide Inhibitor of the Histone Deacetylases","volume":"133","author":"Cole","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1002\/anie.200802043","article-title":"Synthesis and biological activity of largazole and derivatives","volume":"47","author":"Seiser","year":"2008","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1021\/ol100308a","article-title":"Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells","volume":"12","author":"Zeng","year":"2010","journal-title":"Org. Lett."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1016\/j.bmcl.2014.07.006","article-title":"Evaluation of class I HDAC isoform selectivity of largazole analogues","volume":"24","author":"Kim","year":"2014","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1021\/ol900078k","article-title":"Synthesis and histone deacetylase inhibitory activity of largazole analogs: Alteration of the zinc-binding domain and macrocyclic scaffold","volume":"11","author":"Bowers","year":"2009","journal-title":"Org. Lett."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1016\/j.bmc.2017.03.071","article-title":"Synthesis and biological evaluation of largazole zinc-binding group analogs","volume":"25","author":"Kim","year":"2017","journal-title":"Bioorganic Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1021\/jm200432a","article-title":"Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: Synthesis and biological evaluation","volume":"54","author":"Bhansali","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1016\/j.tet.2014.05.078","article-title":"Design, synthesis, and biological evaluation of largazole derivatives: Alteration of the zinc-binding domain","volume":"70","author":"Su","year":"2014","journal-title":"Tetrahedron"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1016\/j.bmc.2011.02.024","article-title":"Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability","volume":"19","author":"Benelkebir","year":"2011","journal-title":"Bioorganic Med. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ejmech.2014.09.009","article-title":"Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups","volume":"86","author":"Bhansali","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Zhang, B., Ruan, Z.W., Luo, D., Zhu, Y., Ding, T., Sui, Q., and Lei, X. (2020). Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole. Mar. Drugs, 18.","DOI":"10.3390\/md18070344"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/cmdc.200900125","article-title":"Synthesis and Biological Evaluation of C7-Demethyl Largazole Analogues","volume":"4","author":"Chen","year":"2009","journal-title":"ChemMedChem"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1021\/jm100244y","article-title":"Synthesis and Biological Characterization of the Histone Deacetylase Inhibitor Largazole and C7- Modified Analogues","volume":"53","author":"Souto","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1021\/ml300371t","article-title":"Biological evaluation of new largazole analogues: Alteration of macrocyclic scaffold with click chemistry","volume":"4","author":"Li","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1021\/acs.jmedchem.5b01044","article-title":"Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities","volume":"58","author":"Yao","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4155\/fmc-2019-0290","article-title":"Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells","volume":"12","author":"Zhang","year":"2020","journal-title":"Futur. Med. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1021\/acs.jmedchem.9b01792","article-title":"Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Diamond, J.R., Kagihara, J.A., Liu, X., Gordon, G., Heim, A.M., Winkler, J., DeMattei, J.A., Piscopio, A.D., and Eckhardt, S.G. (2019, January 26\u201330). OKI-179 is a novel, oral, class I specific histone deacetylase inhibitor in phase 1 clinical trials. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA.","DOI":"10.1158\/1535-7163.TARG-19-B007"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0959-8049(20)31097-2","article-title":"Initial results from a phase 1 trial of OKI-179, an oral Class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors","volume":"138","author":"Diamond","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_144","unstructured":"Liu, X., Phillips, A.J., Ungermannova, D., Nasveschuk, C.G., and Zhang, G. (2016). Macrocyclic Compounds Useful as Inhibitors of Histone Deacetylases. (9,422,340), U.S. Patent."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/2326-6066.CIR-18-0875","article-title":"Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol. Res."}],"container-title":["Marine Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-3397\/19\/9\/488\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:31Z","timestamp":1760165611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-3397\/19\/9\/488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":145,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["md19090488"],"URL":"https:\/\/doi.org\/10.3390\/md19090488","relation":{},"ISSN":["1660-3397"],"issn-type":[{"value":"1660-3397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]}}}